- In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN’s proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN
- In May 2024, T2 Biosystems, Inc. announced a nonbinding Letter of Intent (LOI) to form a strategic partnership with ECO Laboratory. The collaboration aims to introduce the T2Lyme Panel as an LDT for early Lyme disease detection and to establish a leading Lyme testing laboratory in the U.S.
